SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila launches Parkinson's generic drug in the US market

15 Oct 2010 Evaluate

Cadila has launched generic Pramipexole tablets, used for treating Parkinson's disease, in the American market.The company's subsidiary Zydus Cadila has launched the Pramipexole tablets in the strengths of of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg.

The sale of Pramipexole tablets in 2010 is estimated to be USD 632 million according to healthcare information solutions company NDC Health. Pramipexole's patent, which has expired, was held by German drugmaker Boehringer Ingelheim. Parkinson''s disease is a progressive disorder marked by muscle rigidity, weakness, shaking, tremor, and eventually difficulty in walking and talking. 

crackcrack

Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×